Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Apatinib, combined with chemotherapy or alone is effective in treating angiosarcoma

a case report

Liu, Mingyanga; Liu, Yongmina; Guo, Huannana; Fu, Dongweia; Lv, Lilia; Chen, Chunhonga; Li, Yanlinb; Zhang, Wenqianb; Yao, Mingb; Zhao, Limina

doi: 10.1097/CAD.0000000000000738
Case Reports

Angiosarcomas are rare but aggressive tumors with poor prognosis. The treatment of angiosarcomas with vascular endothelial growth factor receptor inhibitors is still in the stage of clinical exploration. Herein we reported a patient of skin angiosarcoma with multiple organ metastasis. She was resistance to multiline chemotherapy and pazopanib but achieved remarkable shrinkage of the lesion after apatinib treatment combined with chemotherapy or alone. The progression-free survival of the primary lesion with KRAS V14I and RBM10 E119D mutations (10 months) was shorter than that of the brain without the mutation ( ≥ 12 months). Although it is not clear whether the KRAS V14I and RBM10 E119D mutations are the main factors that impact the effect of apatinib treatment or not, the results of this study will provide valuable clues for relevant follow-up basic and clinical studies.

aDepartment of Oncology, General Hospital of Heilongjiang Province Land Reclamation Bureau, Harbin

bOrigiMed, Shanghai, China

Received 5 September 2018 Revised form accepted 6 December 2018

Correspondence to Limin Zhao, MM, Department of Oncology, General Hospital of Heilongjiang Province Land Reclamation Bureau, No. 235, Hashuang Road, Nangang District, Harbin, Heilongjiang Province 150088, China Tel: + 86 155 4621 0787; fax: + 86 021 3478 3231; e-mail:

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.